Ides in Highly Sensitized Patients Awaiting Kidney Transplantation
| Status: | Completed |
|---|---|
| Conditions: | Renal Impairment / Chronic Kidney Disease |
| Therapuetic Areas: | Nephrology / Urology |
| Healthy: | No |
| Age Range: | 18 - 70 |
| Updated: | 10/4/2018 |
| Start Date: | April 14, 2015 |
| End Date: | December 30, 2017 |
A Phase I/II Trial to Evaluate the Safety and Tolerability of Ides® (IgG Endopeptidase) to Eliminate Donor Specific HLA Antibodies (DSAs) and Prevent Antibody-Mediated Rejection Post-Transplant in Highly-HLA Sensitized Patients.
IdeS® is an IgG-degrading enzyme of S.pyogenes that cleaves all four human subclasses of IgG
with strict specificity. Alloantibodies are a major deterrent to access to and success of
life-saving organ transplants. We hypothesize that the use of IdeS® pre-transplant in HS
patients will represent a more robust and complete technique to eliminate DSA from the sera
of HS patients. A single dose administration of IdeS® in the pre-operative period to HS
patients with positive DSAs and flow cytometry crossmatches will durably eliminate
circulating DSAs, allow transplantation to occur without ABMR and, in conjunction with
standard desensitization therapy, result in a durable suppression of DSA levels thus
eliminating the risk for ABMR.
with strict specificity. Alloantibodies are a major deterrent to access to and success of
life-saving organ transplants. We hypothesize that the use of IdeS® pre-transplant in HS
patients will represent a more robust and complete technique to eliminate DSA from the sera
of HS patients. A single dose administration of IdeS® in the pre-operative period to HS
patients with positive DSAs and flow cytometry crossmatches will durably eliminate
circulating DSAs, allow transplantation to occur without ABMR and, in conjunction with
standard desensitization therapy, result in a durable suppression of DSA levels thus
eliminating the risk for ABMR.
This is a single center phase I/II open label, dose escalating, exploratory study assessing
safety and efficacy of IdeS® (Hansa Medical, Lund, Sweden) given immediately prior to kidney
transplantation. We hope that IdeS® will help eliminate DSAs in HS patients who are DSA+ and
flow cytometry (FCMX) crossmatch + at time of transplant. We plan to enroll a total of 20
patients. Patients will be followed for 6 months post administration of IdeS®.
safety and efficacy of IdeS® (Hansa Medical, Lund, Sweden) given immediately prior to kidney
transplantation. We hope that IdeS® will help eliminate DSAs in HS patients who are DSA+ and
flow cytometry (FCMX) crossmatch + at time of transplant. We plan to enroll a total of 20
patients. Patients will be followed for 6 months post administration of IdeS®.
Inclusion Criteria:
- End-stage renal disease awaiting transplantation on the UNOS list.
- No known contraindications for therapy with IVIG10%/Rituximab, plasmapheresis (PLEX)
or IdeS®.
- Age 18-70 years at the time of screening.
- Calculated PRA (CPRA)> 50% demonstrated on 3 consecutive samples, Patient highly-HLA
sensitized and a candidate for DD transplantation after desensitization at CSMC.
- At transplant, patient must have donor-specific antibody/ crossmatch positive
(DSA/CMX+) non-HLA identical donor.
- Pre-transplant vaccination with Streptococcus pneumoniae and Nisseria meningitides
- Subject/Parent/Guardian must be able to understand and provide informed consent.
Exclusion Criteria:
- Positivity for anti-IdeS IgE
- Use of IVIG 4 weeks prior to planned IdeS® administration
- Recipients of Extended Criteria Donors (ECD) or Living Donors (LD)
- Lactating or pregnant females.
- Women of child-bearing age who are not willing or able to practice FDA-approved forms
of contraception.
- HIV-positive subjects.
- Subjects who test positive for HBV infection [positive HBVsAg, HBVcAb, or HBVeAg/DNA]
or HCV infection [positive Anti-HCV (EIA) and confirmatory HCV RIBA].
- Subjects with active TB.
- Subjects with selective IgA deficiency, those who have known anti-IgA antibodies, and
those with a history of anaphylaxis or severe systemic responses to any part of the
clinical trial material.
- Subjects who have received or for whom multiple organ transplants are planned.
- Recent recipients of any licensed or investigational live attenuated vaccine(s) within
two months of the screening visit (including but not limited to any of the following:
1. Adenovirus [Adenovirus vaccine live oral type 7]
2. Varicella [Varivax]
3. Hepatitis A [VAQTA]
4. Rotavirus [Rotashield]
5. Yellow fever [Y-F-Vax]
6. Measles and mumps [Measles and mumps virus vaccine live]
7. Measles, mumps, and rubella vaccine [M-M-R-II]
8. Sabin oral polio vaccine
9. Rabies vaccines [IMOVAX Rabies I.D., RabAvert])
- A significantly abnormal general serum screening lab result defined as a WBC < 3.0 X
103/ml, a Hgb < 8.0 g/dL, a platelet count < 100 X 103/ml, , an SGOT > 3X upper limit
.
- Individuals deemed unable to comply with the protocol.
- Subjects with active CMV or EBV infection as defined by CMV-specific serology (IgG or
IgM) and confirmed by quantitative PCR with or without a compatible illness.
- Subjects with a known history of previous myocardial infarction within one year of
screening.
- Subjects with a history of clinically significant thrombotic episodes, and subjects
with active peripheral vascular disease.
- Subjects with Protein C and Protein S deficiency
- Use of investigational agents within 4 weeks of participation.
- Known allergy/sensitivity to IdeS® infusions
We found this trial at
1
site
Cedars Sinai Med Ctr Cedars-Sinai is known for providing the highest quality patient care. Our...
Click here to add this to my saved trials
